A main cause of vision loss in the elderly is age-related macular degeneration (AMD), which profoundly impacts quality of life (Raftery et al., 2007; Chakravarthy et al., 2010; Schaal et al., 2016; Wang et al., 2016a; Al-Zamil et al., 2017). Given the increasing aging population worldwide, the incidence of AMD is projected to increase from 196 million in 2020 to 288 million in 2040 (Wong et al., 2014), placing a significant burden on families and the healthcare system. Demographic, environmental and genetic risk factors all play substantial contributing roles in the pathophysiology of AMD. Among the cellular, biochemical, and molecular changes linked to this disease, inflammation and angiogenesis appear to be critical in AMD pathogenesis and progression (Agrawal and Chaqour, 2014; Kauppinen et al., 2016).
There are two forms of AMD, dry (nonexudative) and wet (exudative, neovascular) (Machalińska et al., 2012). The disease usually begins as the dry type constituting 80–90% of cases, whereas wet AMD represents 10–15% of AMD cases. Dry AMD is associated with retinal pigment epithelium (RPE) and photoreceptor degeneration (Ayoub and Patel, 2009), while wet AMD is associated with choroidal neovascularization and accounts for 90% of clinical cases with severe vision impairment (Bhise et al., 2011; Heiferman and Fawzi, 2019). Characteristic of dry AMD is an altered RPE pigment distribution in the macula, and the generation of pale or yellow deposits called drusen in the space between the RPE and Bruch’s membrane (Johnson et al., 2003; Ayoub and Patel, 2009; Algvere et al., 2016). Bruch’s membrane is the innermost layer of the choroid and lies in apposition to the RPE. Drusen contain a variety of constituents, including lipid and amyloid-β deposits (Isas et al., 2010). Early stage dry AMD patients may remain asymptomatic and it may take years for their vision to be affected (Ayoub and Patel, 2009). In late stage dry AMD there is geographic atrophy (GA) of the RPE and retina, and choroidal neovascularization (CNV) characterizes wet AMD (Ayoub and Patel, 2009). Disease progression in GA AMD is usually slow. CNV AMD is characterized by the growth of leaky blood vessels from the choroid into the retina (Feehan et al., 2011). The new vessels that are formed constitute the choroidal neovascular membrane; they are largely malformed resulting in improper vascular integrity (Senger and Davis, 2011). The blood and fluid leakage within the disrupted tissue provokes inflammation and scar formation resulting in retinal damage and detachment (Witmer et al., 2003). This damage to the retina causes central vision loss and eventual loss of sight if untreated (Bhise et al., 2011; Farnoodian et al., 2017).
Angiogenesis and vascular imbalance are critically involved in this disease, with vascular endothelial growth factor (VEGF), a proangiogenic factor and a key player (Al-Zamil and Yassin, 2017; Farnoodian et al., 2017). Several ocular cells produce VEGF, including RPE cells, endothelial cells, glial cells, and ganglion cells (Bhutto et al., 2008). In addition to stimulating blood vessel growth, VEGF also promotes endothelial cells to synthesize matrix metalloproteinases that proteolytically degrade the extracellular matrix and enable new vessels to form (Vempati et al., 2014). Factors other than VEGF control angiogenesis in AMD, including platelet-derived growth factor, fibroblast growth factors, epidermal growth factor, angiopoietins, and angiogenin (Abdollahi and Folkman, 2010; Bhise et al., 2011; Skeie et al., 2011). Also, several angiogenesis inhibitors including thrombospondin-1, pigment epithelium derived factor, endostatin, and angiostatin are present in the eye environment, and the levels of thrombospondin-1, pigment epithelium derived factor, and endostatin were decreased in Bruch’s membrane in eyes with AMD (Bhutto et al., 2008). Therefore, it seems that a balance of pro- and anti-angiogenic factors is necessary for achieving ocular vascular homeostasis. The production of these factors can be altered by hypoxia, oxidative stress, ischemia, and inflammation (which all increase with age) and thereby disturb this balance, leading to AMD development (Bhise et al., 2011).
The recruitment of macrophages, which release proinflammatory and proangiogenic mediators, has been suggested in both dry and wet AMD (Ambati et al., 2013). The suppression of inflammation and new vessel growth emerge as strategies for the treatment of AMD. Approximately 50% of individuals with extensive macular drusen will progress within 5 years to vision threatening GA and/or neovascularisation (Davis et al., 2005), which are late stage manifestations of the disease (Sunness et al., 1999; Wong et al., 2008). No effective treatment exists at present to prevent the onset or progression of GA (Holz et al., 2014). Anti-VEGF agents are effective in treating choroidal neovascular membrane in wet AMD but have limited success with about 15% of AMD patients not responding to such treatment (Krebs et al., 2013), and are associated with serious systemic adverse events (Martin et al., 2011). Moreover, antiangiogenic treatments require intravitreal injections each month and long-term follow-up. They are invasive and costly (Raftery et al., 2007), with increased risk of intra-ocular infection. In the USA, the visual impairment caused by AMD is forecast to double by 2050 and that antiangiogenic agents will only reduce this by 17% (Rein et al., 2009). Currently, optical coherence tomography and fluorescein fundus angiography performed by an optometrist or ophthalmologist can be used in the diagnosis of AMD and to monitor its progression. However, these procedures cannot be used to predict the disease. A non-invasive and sensitive test would considerably enhance the diagnosis and follow-up process of AMD.
MicroRNAs (miRNAs) are an abundant class of endogenous single-stranded non-coding RNA molecules approximately 22 nucleotides long. They recognize sequences in the 3′-untranslated regions (3′-UTR) of target mRNAs, and either induce mRNA degradation (Bagga et al., 2005) or inhibit their translation (He and Hannon, 2004; Meister, 2007). They are involved in a range of basic cellular processes such as proliferation, differentiation, apoptosis, and cell cycle regulation (Mens and Ghanbari, 2018). Also miRNAs have a major role in regulating various pathological processes involved in AMD pathogenesis, including inflammation and angiogenesis (Kawa and Machalińska, 2014). Previously, miRNAs have been directly linked to retinal diseases e.g., retinitis pigmentosa (Loscher et al., 2007), retinoblastoma (Zhao et al., 2009), and ocular neovascularization (Shen et al., 2008; Dong et al., 2009). Recently, altered expression of inflammatory miRNAs was found in retinal tissue and blood plasma as well as in peripheral blood mononuclear cells from AMD patients (Berber et al., 2017; Lin et al., 2018; Pogue and Lukiw, 2018). Four miRNAs, miR-9, miR-129b, miR-146a, miR-155, were upregulated in whole retina samples from AMD patients compared to controls (Lukiw et al., 2012). The miRNAs present in human serum and plasma have been found to be relatively stable (Gilad et al., 2008) and miRNAs are potential biomarkers which can be used in the diagnosis and prognosis of human diseases (Lässer, 2012; Peplow et al., 2019). Additionally, synthetic miRNAs in artificial exosomes could be applicable for therapeutic approaches by modulating miRNA levels.
Two recent reviews of miRNAs in AMD patients (Berber et al., 2017; Ascou et al., 2018) have drawn attention to important limitations in four research studies published 2014–2016, and these are summarized in Table 1. Notably, there was minimal agreement in the findings between the four studies, and although some miRNAs were found in several of the studies, they did not necessarily concur on the direction of effect due to possible simultaneous therapy. A partial explanation for these discrepancies might lie in the patient inclusion criteria, as one study had included late stage AMD patients, some of whom had received anti-VEGF therapy (Grassmann et al., 2014), while another study had used newly diagnosed patients who had not received any therapy prior to entry into the study (Szemraj et al., 2015). Also, some of the control subjects in the earlier study had glaucoma, while in the later study only controls without ocular abnomalities were included. Other limitiations shown in Table 1 include a failure to perform receiver operating characteristics (ROC) analysis to determine if any of the dysregulated miRNAs can serve to differentiate AMD patients from controls. We have performed a PubMed literature search of research articles published in the period 1 January 2014 to 31 December 2019 on miRNAs in dry and wet AMD and which includes the four mentioned studies published in 2014–2016. The goal is to identify miRNA biomarkers of high sensitivity and specificity in early-stage AMD, and using a panel of miRNAs or ratio of two miRNAs may be an important method to accomplish this. Also, this is to provide further information on miRNA dysregulation in AMD patients, and whether the weaknesses or limitations identified in the four earlier studies have been taken into account or overcome in the later studies.
MicroRNAs and Age-Related Macular Degeneration
The steps involved in this review and its contents are shown (Figure 1). A total of thirteen research articles were found in the PubMed search of which one had utilized whole blood, two peripheral blood nuclear cells, two blood plasma, five blood serum, one exosomes from blood serum, one blood plasma and vitreous humour, and one retinal tissues. All of the studies reported using RT-PCR or PCR for quantitative measurement of miRNAs except for one which had used miRNA array analysis. All of the studies except for two had reportedly included both male and female subjects – one had not reported on gender composition of the AMD and control subjects, and in another study all the samples were from females. There was often a disproportion of the two genders in the study groups and also differences in their mean ages. Moreover, while several of the studies had recruited quite large cohorts of AMD and control patients e.g., one study had 175 dry AMD, 179 wet AMD, and 121 healthy control (HC) individuals (Ulańczyk et al., 2019), there were several others that were performed with much smaller cohorts e.g., one had used 11 wet AMD and 11 HC subjects (Romano et al., 2017). While many of the studies had reported on criteria for patient inclusion, exclusion criteria were often not reported. Three of the studies had adjusted their data for age, gender, and smoking status (Grassmann et al., 2014; Litwińska et al. 2019; Ulańczyk et al. 2019). Use of ROC analysis with area under curve (AUC) values to establish which miRNAs are good or fair tests to distinguish AMD patients from HC, and to differentiate between dry AMD and wet AMD patients, was only reported in four studies (Grassman et al., 2014; Menard et al., 2016; Ren et al., 2017; Lin et al., 2018). Sensitivity and specificity values of specific miRNAs as biomarkers of AMD disease were only provided in one study (Ren et al., 2017). These are all important limitations (Table 1).
The relevant findings from the research articles in the PubMed search are summarized as follows.
By RT-PCR analysis, Ren et al. (2017) showed that the expression of miR-27a-3p, miR-29b-3p, miR-195-5p was increased (increase ratios 2.68, 3.53, 4.23 times, respectively) in 72 dry AMD and 54 wet AMD patients compared to 140 HC. All three microRNAs miR-27a-3p, miR-29b-3p, miR-195-5p were increased in both dry AMD and wet AMD patients. The expression of miR-27a-3p was higher in wet AMD compared to dry AMD patients, but there were no significant differences of miR-29b-3p and miR-195-5p expression between dry AMD and wet AMD patients. ROC analysis for miR-27a-3p, miR-29b-3p, miR-195-5p to differentiate AMD from HC gave AUC values of 0.925, 0.757 and 0.766, respectively, with 0.825 sensitivity/0.728 specificity when miR-27a-3p ≥ 12.0, 0.688 sensitivity/0.718 specificity when miR-29b-3p ≥ 10.6, and 0.726 sensitivity/0.596 specificity when miR-195-5p ≥ 10.2. Thus, whole blood miR-27a-3p was a potential diagnostic biomarker of AMD.
Peripheral blood nuclear cells
Litwińska et al. (2019) using RT-PCR with peripheral blood nuclear cells (PBNCs) isolated from plasma of 175 dry AMD, 179 wet AMD, and 121 HC subjects showed that expression of miR-23a-3p, miR-30b, miR-191-5p, miR-223-3p was increased whereas that of miR-16-5p, miR-17-3p, miR-150-5p, miR-155-5p was decreased in PBNCs of wet AMD patients compared to HC. Multivariate analysis of patients and controls, adjusted for age, sex, and smoking status (pack-years), indicated that wet AMD was an independent factor associated with increased expression of miR-23a-3p, miR-30b, miR-191-5p, and decreased expression of miR-16-5p, miR-17-3p, miR-150-5p, miR-155-5p. Dry AMD patients had increased expression of miR-23a-3p, miR-126-3p, miR-126-5p, miR-146a and decreased expression of miR-16-5p, miR-17-3p, miR-17-5p in PBNCs compared to controls. Multivariate analysis revealed that dry AMD was an independent factor associated with increased expression of miR-23a-3p, miR-126-3p, miR-126-5p, miR-146a, miR-191-5p and decreased expression of miR-16-5p, miR-17-3p, miR-17-5p. Six miRNAs were differentially expressed in PBNCs of AMD subtypes: four were increased in dry AMD patients (miR-126-3p, miR-126-5p, miR-150-5p, miR-155-5p) whereas two were increased in wet AMD patients (miR-30b, miR-191-5p). Visual acuity and expression of miR-126-3p, miR-126-5p, miR-155-5p were positively correlated, whereas visual acuity and miR-191-5p expression were negatively correlated. The control group did not have such correlations. A smaller scale study by Lin et al. (2018) using RT-PCR with peripheral blood mononuclear cells (PBMCs) from 20 early AMD patients (with moderate drusen > 63 mm or pigment changes in at least 1 eye but no CNV or GA in either eye at time of sample collection), 23 advanced NV AMD patients, and 63 HC showed that both early AMD and NV AMD patients had increased PBMC expression of miR-150 compared to HC, but PBMC miR-150 expression in early AMD and NV AMD patients did not differ from each other. ROC analysis for PBMC miR-150 expression gave an AUC value 0.860, showing good discrimination of NV AMD from HC. Upregulation of miR-150 in PBMCs was associated with increased likelihood of AMD, even after accounting for differences in age.
Ulańczyk et al. (2019) found using RT-PCR analysis of blood plasma samples that the expression of miR-16-5p, miR-17-3p, miR-17-5p, miR-23a-3p, miR-126-5p, miR-146a, miR-223-3p was increased whereas that of miR-21-3p, miR-155-5p, miR-191-5p was decreased in 175 dry AMD and 179 wet AMD patients compared to 121 HC subjects. In multivariate analysis, AMD was an independent factor associated with higher expression of miR-23a-3p, miR-126-5p, miR-16-5p, miR-17-3p, miR-17-5p, miR-223-3p, and miR-93 and lower expression of miR-21-3p and miR-155-5p. Wet AMD patients had significantly increased expression of miR-16-5p, miR-30b, miR-191-5p, and significantly decreased expression of miR-23a-3p, compared to dry AMD patients. Visual acuity and blood plasma miR-23a-3p were negatively correlated in AMD patients but not in the control group. The expression of analyzed miRNAs correlated with the levels of tested angiogenesis-regulating factors and clinical parameters in AMD patients but not in the controls. In a small scale study, Ménard et al. (2016) observed by PCR analysis that the expression of miR-146a was increased while that of miR-106b and miR-152 was decreased in blood plasma from 13 CNV AMD patients (fold changes ~2.5, ~1.5, ~1.7 respectively) compared to 13 controls. ROC analysis gave an AUC value 0.914 for the miR-146a/miR-106b ratio in blood plasma for discriminating CNV AMD patients from controls. Ertekin et al. (2014) also used small sized cohorts of 33 wet AMD and 31 HC subjects and found using RT-PCR that the expression of miR-20a-5p, miR-106a-5p, miR-24-3p, miR-17-5p, miR-223-3p was increased while that of miR-140-3p, miR-21-5p, miR-25-3p, miR-146b-5p, miR-192-5p, miR-335-5p, miR-342-3p, miR-374a-5p, miR-410, miR-660-5p, miR-574-3p was decreased in blood plasma of wet AMD patients compared to controls. Furthermore, miR-26b-5p, miR-27b-3p, miR-29a-3p, miR-139-3p, miR-212-3p, miR-324-3p, miR-324-5p, miR-532-3p, miR-744-5p, let-7c were expressed only in the wet AMD group. Dysregulated miRNAs that target VEGFA gene were miR-20b-5p, miR-24-3p, miR-106a-5p, miR-17-5p (all upregulated) and miR-335-5p (downregulated).
Blasiak et al. (2019) using RT-PCR analysis of blood serum samples from 76 wet AMD and 70 HC subjects showed that 4 out of 18 miRNAs regulating the expression of the VEGFA gene, miR-34a-5p, miR-126-3p, miR-145-5p, miR-205-5p, had lower expression in wet AMD patients than in controls, using Benjamin-Hochberg correction. In a larger study with 100 AMD and 100 HC individuals, Szemraj et al. (2017) observed by RT-PCR an increased expression of miR-145 and a decreased expression of miR-31, miR-149 and miR-182 in blood serum of AMD patients compared to controls. Romano et al. (2017) performed a small scale study comprising 11 CNV AMD and 11 HC subjects, and found by RT-PCR a higher expression of miR-9, miR-23a, miR-27a, miR-34a, miR-126 and miR-146a together with a lower expression of miR-155 in blood serum of CNV AMD patients compared to controls. The dysregulated miRNAs targeted the VEGF pathway. Utilizing larger sized cohorts of 150 dry AMD and 150 wet AMD patients together with 200 HC subjects, Szemraj et al. (2015) reported a higher expression of miR-661, miR-3121, miR-4258, miR-889, miR-438, miR-424-5p, miR-301-5p and let-7 in blood serum from both dry AMD and wet AMD patients compared to controls. The expression of miR-661 (4.7x), miR-3121 (3x) was greater in dry AMD than wet AMD, while that of miR-4258 (3.3x), miR-889 (3x) and let-7 (2.6x) was greater in wet AMD than dry AMD. The levels of miR-438, miR-424-5p and miR-301-5p were not significantly different between dry AMD and wet AMD. Grassmann et al. (2014) recruited 59 GA AMD, 129 NV AMD and 147 HC subjects, and by RT-PCR showed decreased expression of miR-301a-3p, miR-361-5p and miR-424-5p in blood serum in NV AMD patients compared to controls, but the levels of these miRNAs did not differ in GA AMD patients compared to controls. Blood serum miR-424-5p expression in GA AMD patients was higher than in NV AMD patients, but expression of miR-301a-3p and miR-361-5p did not differ between GA AMD and NV AMD patients. ROC analysis of the combined three miRNAs gave an AUC value 0.727 for distinguishing NV AMD from HC. In this study, the data had been adjusted for age, gender, and smoking (pack years).
Blood serum exosomes
RT-PCR analysis of exosomes isolated from blood serum of 70 wet AMD and 50 HC subjects by Elbay et al. (2019) revealed upregulation of miR-486-5p and miR-626, and downregulation of miR-885-5p, in wet AMD compared to controls. These three miRNAs are involved in the apoptosis and neovascularization pathways of wet AMD pathogenesis.
Ménard et al. (2016) using PCR analysis of vitreous humour from 13 CNV AMD patients and 13 controls found that expression of miR-146a was increased whereas that of miR-152 and miR-106b was decreased in CNV AMD (fold changes ~3, ~3, ~4, respectively) compared to controls. By ROC analysis, the AUC value for miR-146a/miR-106b ratio was 0.977 in the vitreous humour indicating it has potential to distinguish between CNV AMD and controls.
By miRNA array analysis of 17 AMD retinal tissue samples (affected macular region) and 10 control retinal tissue samples, Pogue and Lukiw (2018) observed that miR-125b, miR-146a and miR-155 had increased expression in AMD tissues compared to controls.
Those miRNAs that can be considered as potential biomarkers of AMD and its subtypes in whole blood, peripheral blood nuclear cells, blood plasma, blood serum, exosomes isolated from blood serum, vitreous humour, and retinal tissues are summarized (Table 2).
Usually disease symptoms develop gradually in dry AMD (Harvard Clinic), which is an early stage of the disease, making it difficult to detect and irreversible changes in vision can occur when the condition converts to wet AMD. No approved or effective treatment exists at present to prevent the onset or progression of geographic atrophy, and treatment of choroidal neovascularization in wet AMD involves regular intravitreal injections of anti-VEGF agents that are burdensome for patients. Furthermore, a proportion of wet AMD patients do not respond to anti-VEGF therapies, and treatments become less effective with repeated injections (Ehlken et al., 2014). Early diagnosis of AMD is important and will allow new medications to be trialed earlier as future treatments may be more successful when given early. Also early diagnosis provides patients and their families with more time to make future plans.
Optical coherence tomography is an important imaging procedure in the diagnosis and management of patients with choroidal neovascularization, allowing the identification of active neovascular membranes. It is also used to monitor treatment response to anti-VEGF agents (Garcia-Layana et al., 2017). A new non-invasive imaging procedure called optical coherence tomography angiography allows the choriocapillaris in late stage AMD to be examined (Garcia-Layana et al., 2017) This technique has also enabled the detection of small blood vessels in the retina of patients with Alzheimer’s disease and mild cognitive impairment (Yoon et al., 2019).
No approved biomarker is available at present for early AMD detection. However, miRNA profiling might reveal potential diagnostic biomarkers of early stage AMD and wet AMD. Recent reviews have indicated miRNAs as non-invasive diagnostic and prognostic biomarkers in many neurodegenerative diseases including Alzheimer’s disease, diabetic retinopathy, and multiple sclerosis (Martinez and Peplow, 2019a, b; Martinez and Peplow, 2020). For example, they allow the detection of mild cognitive impairment which represents early stage Alzheimer’s disease (Martinez and Peplow, 2019a) and of nonproliferative diabetic retinopathy which is the early stage of diabetic retinopathy (Martinez and Peplow, 2019b). Interestingly, both Alzheimer’s disease and diabetic retinopathy are associated with an increased risk of AMD development (Williams et al., 2014; Frost et al., 2016; He et al., 2018), and AMD and diabetic retinopathy are associated with increased risk of Alzheimer’s disease (Lee et al., 2019). These findings suggest shared pathological pathways in these three diseases. Profiling of miRNAs could provide new insights into the pathophysiology of AMD co-shared with Alzheimer’s disease and diabetic retinopathy, but also novel biomarkers for more accurate diagnosis and likely prognosis of AMD.
A very large number of miRNAs were found to be dysregulated in the different studies reviewed, but with limited overlap between individual studies (Table 2). Of those where there was overlap, miR-23a-3p and miR-126-5p were upregulated in PBNCs of dry AMD patients (Litwińska et al., 2019) and in blood plasma of AMD patients (Ulańczyk et al., 2019). Also, miR-23a and miR-126 were upregulated in blood serum of wet AMD patients (Romano et al., 2017). MiR-146a was upregulated in PBNCs of dry AMD patients (Litwińska et al., 2019), and in blood plasma and vitreous humour of wet AMD patients (Ménard et al., 2016). Both miR-146a and miR-155 were upregulated in AMD retinal tissues collected at postmortem (Pogue and Lukiw, 2018) and confirmed the findings reported earlier (Lukiw et al., 2012). However, miR-155 was downregulated in PBMCs of wet AMD patients (Litwińska et al., 2019), blood plasma of AMD patients (Ulańczyk et al., 2019), and blood serum of CNV AMD patients (Romano et al., 2017). MiR-17-5p and miR-223-3p were upregulated in blood plasma of AMD patients (Ulańczyk et al., 2019) and wet AMD patients (Ertekin et al, 2014). Also comparing wet AMD patients with dry AMD patients, miR-30b and miR-191-5p were upregulated in PBNCs (Litwińska et al., 2019) and blood plasma (Ulańczyk et al., 2019). The expression of the dysregulated miRNAs in AMD patients was found to be significantly correlated with angiogenesis-regulating factors particularly angiogenin and endostatin (Ulańczyk et al., 2019). For example, upregulated miR-17-5p in the blood plasma of AMD patients showed a positive corelation with angiogenin and endostatin, while upregulated miR-23a-3p, miR-146a and miR-223-3p had a negative corelation with angiogenin and endostatin (Ulańczyk et al., 2019). The downregulated miR-34a-5p, miR-126-3p, miR-145-5p, and miR-205-5p in the blood serum of wet AMD patients target the VEGFA gene (Blasiak et al., 2019), and the set of miRNAs dysregulated in blood serum of wet AMD patients target the VEGF pathway (Romano et al, 2017). Downregulated miR-361-5p in the blood serum of wet AMD patients (Grassmann et al., 2014) should influence angiogenesis, as this miRNA was shown to alter the level of VEGFA expression (Kanitz et al., 2012). In addition, the expression of analyzed miRNAs strongly correlated with the levels of tested inflammatiory mediators in AMD patients, and negative correlations of two factors strongly elevated in wet AMD patients, interleukin-4 and interleukin-6, with miR-30b and miR-146a occurred in wet AMD but not in dry AMD (Litwińska et al., 2019).
Specific miRNAs previously reported to be involved in angiogenesis or neovascularization have included miR-10, miR-27a, miR-126, miR-145, miR-195 (Hassel et al., 2012; Sasahira et al., 2012; Xu et al., 2012; Lai et al., 2013; Wang et al., 2013, 2016b), miR-155 (Pankratz et al., 2015), miR-130a (Chen and Gorski, 2008), miR-93 (Wang et al., 2016a), miR-23, miR-27, miR-24 (Sabatel et al., 2011; Zhou et al., 2011, 2014), miR-106a, miR-146, miR-181, miR-199a, miR-214, miR-424, miR-451, miR-31, miR-150, miR-184 (Shen et al., 2008), miR-21, miR-132, miR-296, miR-378, miR-519c (Lee et al., 2007; Würdinger, et al., 2008; Anand et al., 2010; Cha et al., 2010; Liu et al., 2011). Figure 2 indicates which of these miRNAs were dysregulated in AMD patients from the studies reviewed herein. Several of the miRNAs were dysregulated in both dry and wet AMD and may be potential biomarkers for detecting dry AMD and monitoring its progression to wet AMD e.g., miR-27a-3p and miR-195-5p in whole blood, miR-23a-3p in PBNCs, miR-150 in PBMCs, and miR-424-5p in blood serum. Expression levels of miR-27a-3p in whole blood (Ren et al., 2017) and miR-424-5p in blood serum (Grassmann et al., 2014) had allowed distinguishing of dry and wet AMD patients (Table 2). Some conflicting findings were apparent with miR-126 and miR-424-5p both increased and decreased in blood serum of wet AMD patients. Although upregulated compared to controls, Szemraj et al. (2015) had found a non-significant lowering of miR-424-5p expression in wet AMD compared to dry AMD patients. It is not clear why miR-126 in blood serum was found to be increased by Romano et al. (2017) whereas miR-126-3p in blood serum was reported to be decreased by Blasiak et al. (2019) but it could relate to the sizes of the study cohorts or whether it was the 3p strand that was measured by Romano et al. (2017). It is considered that miR-27a-3p in whole blood and miR-424-5p in blood serum are promising candidates as biomarkers for further research and validation in AMD patients.
Of interest, miR-125b, miR-146a and miR-155 were found to be upregulated in AMD-affected macular region of the retina and Alzheimer’s disease superior temporal lobe neocortex (Pogue and Lukiw, 2018) and it was suggested that addressing the common mechanisms of aging that lead to different age-related diseases might assist in identifying new therapeutic approaches. Treatment modalities targeting Alzheimer’s disease might be applicable to AMD. Immunotherapies targeting amyloid peptides showed that a decrease in amyloid plaques improved cognitive function in mouse models of Alzheimer’s disease (Morgan et al., 2000; Castillo-Carranza et al., 2013), and anti-amyloid therapy protected the retinal pigment epithelium in a mouse model of AMD (Ding et al., 2008, 2011). However, a randomized Phase 2 clinical trial of an anti-amyloid β monoclonal antibody GSK933776 administered intravenously for the treament of GA in AMD did not decrease the rate of GA enlargement and no clinically important changes in visual function testing were found over 18 months compared to placebo (Rosenfeld et al., 2018). A recent clinical trial using a cell implant method has shown promising results for advanced dry AMD. A layer of human retinal pigment epithelial cells on a thin supporting structure was implanted into the retina and trialed in four patients with advanced dry AMD who were then monitored for a year. The implant was found to have integrated into the patients’ own retinal tissue. One patient had improved visual acuity and two other patients gained some visual function. None of the four patients had further progression of vision loss during the year following therapy (Kashani et al., 2018). Moreover, intravitreal injection of stem cells may be a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases (Puertas-Neyra et al., 2020). At present there has been relatively little research into the therapeutic potential of miRNAs for the treatment of AMD (Natoli and Fernando, 2018). Studies with miRNA mimics or inhibitors in animal models of AMD may provide an insight into how these unique treatments might provide a beneficial effect on retinal function.
To summarize, there has been considerable progress made in the recent studies in this review with regard to distinguishing dry AMD and wet AMD from controls and between each other by analyzing miRNAs in whole blood, peripheral blood nuclear cells, blood plasma, blood serum, exosomes from blood serum, vitreous humour, and retinal tissues, and have included single and combinations of miRNAs as well as a ratio of two miRNAs. In the four previous studies (Table 1) limitations included small group sizes, heterogeneity of AMD and HC groups, patient inclusion criteria, analytical methods with normalization, and statistical analysis. While these have been taken into account in many of the recent studies, some concerns still exist regarding recruitment of patients including numbers, gender, selection criteria, stage of disease, comorbidities/current treatment, most appropriate validation method, and statistical analysis of data. Also specific measures of miRNAs as diagnostic markers of dry and wet AMD such as sensitivity and specificity values were mainly absent. It is hoped that by continuing to address these concerns in the planning and implementation of future studies a sensitive and specific, minimally invasive test can be developed to identify patients with dry AMD and assist with regular monitoring or with wet AMD to initiate treatment and slow disease progression.
1. Abdollahi A, Folkman J. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy Drug Resist Updat. 2010;13:16–28
2. Agrawal S, Chaqour B. MicroRNA signature and function in retinal neovascularization World J Biol Chem. 2014;5:1–11
3. Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration Clin Interv Aging. 2017;12:1313–1330
4. Algvere PV, Kvanta A, Seregard S. Drusen maculopathy: a risk factor for visual deterioration Acta Ophthalmol. 2016;94:427–433
5. Ambati J, Atkinson JP, Gelfand BD. Immunology of age-related macular degeneration Nat Rev Immunol. 2013;13:438–451
6. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, King PD, Weis SM, Cheresh DA. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis Nat Med. 2010;16:909–914
7. Ascou AL, Alsing S, Holmgaard A, Bek T, Corydon TJ. Dissecting microRNA dysregulation in age-related macular degeneration: new targets for eye gene therapy Acta Ophthalmol. 2018;96:9–23
8. Ayoub T, Patel N. Age-related macular degeneration J R Soc Med. 2009;102:56–61
9. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation Cell. 2005;122:553–563
10. Berber P, Grassmann F, Kiel C, Weber BH. An eye on age-related macular degeneration: the role of microRNAs in disease pathology Mol Diagn Ther. 2017;21:31–43
11. Bhise NS, Shmueli RB, Sunshine JC, Tzeng SY, Green JJ. Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis Expert Opin Drug Deliv. 2011;8:485–504
12. Bhutto IA, Uno K, Merges C, Zhang L, McLeod DS, Lutty GA. Reduction of endogenous angiogenesis inhibitors in Bruch’s membrane of the submacular region in eyes with age-related macular degeneration Arch Ophthalmol. 2008;126:670–678
13. Blasiak J, Watala C, Tuuminen R, Kivinen N, Koskela A, Uusitalo-Järvinen H, Tuulonen A, Winiarczyk M, Mackiewicz J, Zmorzyński S, Filip A, Kaarniranta K. Expression of VEGFA-regulating miRNAs and mortality in wet AMD J Cell Mol Med. 2019;23:8464–8471
14. Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R. Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target Immunotargets Ther. 2013;3:19–28
15. Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM, Yu SL, Chen JS, Chang KJ, Jee SH, Tan CT, Lin MT, Kuo ML. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis Cancer Res. 2010;70:2675–2685
16. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis BMC Ophthalmol. 2010;10:31
17. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5 Blood. 2008;111:1217–1226
18. Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, Ferris FL, Bressler SB, Milton RC. The Age-related Eye Disease Study severity scale for age-related macular degeneration: AREDS report No.17 Arch Ophthalmol. 2005;123:1484–1498
19. Ding JD, Lin J, Mace BE, Herrmann R, Sullivan P, Bowes Rickman C. Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model Vision Res. 2008;48:339–345
20. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M, Mace BE, Sullivan P, Jamison JA, Kelly U, Harrabi O, Bollini SS, Dilley J, Kobayashi D, Kuang B, Li W, Pons J, Lin JC, Bowes Rickman C. Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration Proc Natl Acad Sci U S A. 2011;108:E279–287
21. Dong A, Xie B, Shen J, Yoshida T, Yokoi K, Hackett SF, Campochiaro PA. Oxidative stress promotes ocular neovascularization J Cell Physiol. 2009;219:544–552
22. Ehlken C, Jungmann S, Böhringer D, Agostini HT, Junker B, Pielen A. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD Eye (Lond). 2014;28:538–545
23. Elbay A, Ercan Ç, Akbaş F, Bulut H, Ozdemir H. Three new circulating microRNAs may be associated with wet age-related macular degeneration Scand J Clin Lab Invest. 2019;79:388–394
24. Etekin S, Yıldırım O, Dinç E, Ayaz L, Fidancı SB, Tamer L. Evaluation of circulating miRNAs in wet age-related macular degeneration Mol Vis. 2014;20:1057–1066
25. Farnoodian M, Wang S, Dietz J, Nickells RW, Sorenson CM, Sheibani N. Negative regulators of angiogenesis: important targets for treatment of exudative AMD Clin Sci (Lond). 2017;131:1763–1780
26. Feehan M, Hartman J, Durante R, Morrison MA, Miller JW, Kim IK, DeAngelis MM. Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics BMC Med Genet. 2011;12:83
27. Frost S, Guymer R, Aung KZ, Macaulay SL, Sohrabi HR, Bourgeat P, Salvado O, Rowe CC, Ames D, Masters CL, Martins RN, Kanagasingam Y. Alzheimer’s disease and the early signs of age-related macular degeneration Curr Alzheimer Res. 2016;13:1259–1266
28. Garcia-Layana A, Ciuffo G, Zarranz-Ventura J, Alvarez-Vidal A. Optical coherence tomography in age-related macular degeneration 2017Accessed 18 February 2020 https://amdbookorg/content/optical-coherence-tomography-age-related-macular-degeneration
29. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A. Serum microRNAs are promising novel biomarkers PLoS One. 2008;3:e3148
30. Grassmann F, Schoenberger PG, Brandl C, Schick T, Hasler D, Meister G, Fleckenstein M, Lindner M, Helbig H, Fauser S, Weber BH. A circulating microrna profile is associated with late-stage neovascular age-related macular degeneration PLoS One. 2014;9:e107461
32. Hassel D, Cheng P, White MP, Ivey KN, Kroll J, Augustin HG, Katus HA, Stainier DY, Srivastava D. MicroRNA-10 regulates the angiogenic behavior of zebrafish and human endothelial cells by promoting vascular endothelial growth factor signaling Circ Res. 2012;111:1421–1433
33. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation Nat Rev Genet. 2004;5:522–531
34. He MS, Chang FL, Lin HZ, Wu JL, Hsieh TC, Lee YC. The association between diabetes and age-related macular degeneration among the elderly in Taiwan Diabetes Care. 2018;41:2202–2211
35. Heiferman MJ, Fawzi AA. Progression of subclinical choroidal neovascularization in age-related macular degeneration PLoS One. 2019;14:e0217805
36. Holz FG, Strauss EC, Schmitz-Valckenberg S, van Lookeren Campagne M. Geographic atrophy: clinical features and potential therapeutic approaches Ophthalmology. 2014;121:1079–1091
37. Isas JM, Luibl V, Johnson LV, Kayed R, Wetzel R, Glabe CG, Langen R, Chen J. Soluble and mature amyloid fibrils in drusen deposits Invest Ophthalmol Vis Sci. 2010;51:1304–1310
38. Johnson PT, Lewis GP, Talaga KC, Brown MN, Kappel PJ, Fisher SK, Anderson DH, Johnson LV. Drusen-associated degeneration in the retina Invest Ophthalmol Vis Sci. 2003;44:4481–4488
39. Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GF, Gerber AP, Detmar M. The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma PLoS One. 2012;7:e49568
40. Kashani AH, Lebkowski JS, Rahhal FM, Avery RL, Salehi-Had H, Dang W, Lin CM, Mitra D, Zhu D, Thomas BB, Hikita ST, Pennington BO, Johnson LV, Clegg DO, Hinton DR, Humayun MS. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration Sci Transl Med. 2018;10:eaao4097
41. Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K. Inflammation and its role in age-related macular degeneration Cell Mol Life Sci. 2016;73:1765–1786
42. Kawa M, Machalińska A. The role of microRNA in the pathogenesis of age-related macular degeneration: its pathophysiology and potential pharmacological aspects J Biochem Pharmaacol Res. 2014;2:21–32
43. Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S. Non- responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration Br J Ophthalmol. 2013;97:1443–1446
44. Lai Y, Zhang X, Zhang Z, Shu Y, Luo X, Yang Y, Wang X, Yang G, Li L, Feng Y. The microRNA-27a: ZBTB10-specificity protein pathway is involved in follicle stimulating hormone-induced VEGF, Cox2 and survivin expression in ovarian epithelial cancer cells Int J Oncol. 2013;42:776–784
45. Lässer C. Exosomal RNA as biomarkers and the therapeutic potential of exosome vectors Expert Opin Biol Ther. 2012;12(Suppl 1):S189–197
46. Lee CS, Larson EB, Gibbons LE, Lee AY, McCurry SM, Bowen JD, McCormick WC, Crane PK. Associations between recent and established ophthalmic conditions and risk of Alzheimer’s disease Alzheimers Dement. 2019;15:34–41
47. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression Proc Natl Acad Sci U S A. 2007;104:20350–20355
48. Lin JB, Moolani HV, Sene A, Sidhu R, Kell P, Lin JB, Dong Z, Ban N, Ory DS, Apte RS. Macrophage microRNA-150 promotes pathological angiogenesis as seen in age-related macular degeneration JCI Insight. 2018;3:120157
49. Litwińska Z, Sobuś A, Łuczkowska K, Grabowicz A, Mozolewska-Piotrowska K, Safranow K, Kawa MP, Machaliński B, Machalińska A. The interplay between systemic inflammatory factors and microRNAs in age-related macular degeneration Front Aging Neurosci. 2019;11:286
50. Liu LZ, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, Kung HF, Lai L, Jiang BH. MiR- 21 induced angiogenesis through AKT and ERK activation and HIF-1α expression PLoS One. 2011;6:e19139
51. Loscher CJ, Hokamp K, Kenna PF, Ivens AC, Humphries P, Palfi A, Farrar GJ. Altered retinal microRNA expression profile in a mouse model of retinitis pigmentosa Genome Biol. 2007;8:R248
52. Lukiw WJ, Andreeva TV, Grigorenko AP, Rogaev EI. Studying micro RNA function and dysfunction in Alzheimer’s disease Int J Biochem Mol Biol. 2012;3:105–116
53. Machalińska A, Kawa MP, Marlicz W, Machaliński B. Complement system activation and endothelial dysfunction in patients with age-related macular degeneration (AMD): possible relationship between AMD and atherosclerosis Acta Ophthamol. 2012;90:695–703
54. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Eng J Med. 2011;364:1897–1908
55. Martinez B, Peplow PV. MicroRNAs as diagnostic and therapeutic tools for Alzheimer’s disease: Advances and limitations Neural Regen Res. 2019a;14:242–255
56. Martinez B, Peplow PV. MicroRNAs as biomarkers of diabetic retinopathy and disease progression Neural Regen Res. 2019b;14:1858–1869
57. Martinez B, Peplow PV. MicroRNAs in blood and cerebrospinal fluid as diagnostic markers of multiple sclerosis and to monitor disease progression Neural Regen Res. 2020;15:606–619
58. Meister G. miRNAs get an early start on translational silencing Cell. 2007;131:25–28
59. Ménard C, Rezende FA, Miloudi K, Wilson A, Tétreault N, Hardy P, SanGiovanni JP, De Guire V, Sapieha P. MicroRNA signatures in vitreous humour and plasma of patients with exudative AMD Oncotarget. 2016;7:19171–19184
60. Mens MM, Ghanbari M. Cell cycle regulation of stem cells by microRNAs Stem Cell Rev Rep. 2018;14:309–322
61. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease Nature. 2000;408:982–985
62. Natoli R, Fernando N. MicroRNA as therapeutics for age-related macular degeneration Adv Exp Med Biol. 2018;1074:37–43
63. Pankratz F, Bemtgen X, Zeiser R, Leonhardt F, Kreuzaler S, Hilgendorf I, Smolka C, Helbing T, Hoefer I, Esser JS, Kustermann M, Moser M, Bode C, Grundmann S. MicroRNA-155 exerts cell-specific antiangiogenic but proarteriogenic effects during adaptive neovascularization Circulation. 2015;131:1575–1589
64. Peplow PV, Martinez B, Calin GA, Esquila-Kerscher A MicroRNAs in Diseases and Disorders. 2019 London, UK RSC Publishing
65. Pogue AI, Lukiw WJ. Up-regulated pro-inflammatory microRNAs (miRNAs) in Alzheimer’s disease and age-related macular degeneration (AMD) Cell Mol Neurobiol. 2018;38:1021–1031
66. Puertas-Neyra K, Usategui-Martin R, Coco RM, Fernandez-Bueno I. Intravitreal stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases Neural Regen Res. 2020;15:1631–1638
67. Raftery J, Clegg A, Jones J, Tan S, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness Br J Ophthalmol. 2007;91:1244–1246
68. Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments Arch Ophthalmol. 2009;127:533–540
69. Ren C, Liu Q, Wei Q, Cai W, He M, Du Y, Xu D, Wu Y, Yu J. Circulating miRNAs as potential biomarkers of age-related macular degeneration Cell Physiol Biochem. 2017;41:1413–1423
70. Romano GL, Platania CBM, Drago F, Salomone S, Ragusa M, Barbagallo C, Di Pietro C, Purrello M, Reibaldi M, Avitabile T, Longo A, Bucolo C. Retinal and circulating miRNAs in age-related macular degeneration: an in vivo animal and human study Front Pharmacol. 2017;8:168
71. Rosenfeld PJ, Berger B, Reichel E, Danis RP, Gress A, Ye L, Magee M, Parham LR, McLaughlin MM. A randomized phase 2 study of an anti-amyloid β monoclonal antibody in geographic atrophy secondary to age-related macular degeneration Ophthalmol Retina. 2018;2:1028–1040
72. Sabatel C, Malvaux L, Bovy N, Deroanne C, Lambert V, Gonzalez ML, Colige A, Rakic JM, Noël A, Martial JA, Struman I. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells PLoS One. 2011;6:e16979
73. Sasahira T, Kurihara M, Bhawal UK, Ueda N, Shimomoto T, Yamamoto K, Kirita T, Kuniyasu H. Downregulation of miR-126 induces angiogenesis and lymphangiogenesis by activation of VEGF-A in oral cancer Br J Cancer. 2012;107:700–706
74. Schaal KB, Rosenfeld PJ, Gregori G, Yehoshua Z, Feuer WJ. Anatomic clinical trial endpoints for non-exudative age-related macular degeneration Ophthalmology. 2016;123:1060–1079
75. Senger DR, Davis GE. Angiogenesis Cold Spring Harb Perspect Biol. 2011;3:a005090
76. Shen J, Yang X, Xie B, Chen Y, Swaim M, Hackett SF, Campochiaro PA. MicroRNAs regulate ocular neovascularization Mol Ther. 2008;16:1208–1216
77. Skeie JM, Zeng S, Faidley EA, Mullins RF. Angiogenin in age-related macular degeneration Mol Vis. 2011;17:576–582
78. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian Y, Hawkins B, Barron Y, Bergman A. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of age-related macular degeneration Ophthalmology. 1999;106:1768–1779
79. Szemraj M, Bielecka-Kowalska A, Oszajca K, Krajewska M, Goś R, Jurowski P, Kowalski M, Szemraj J. Serum microRNAs as potential biomarkers of AMD Med Sci Monit. 2015;21:2734–2742
80. Szemraj M, Oszajca K, Szemraj J, Jurowski P. MicroRNA expression analysis in serum of patients with congenital hemochromatosis and age-related macular degeneration (AMD) Med Sci Monit. 2017;23:4050–4060
81. Ulańczyk Z, Sobuś A, Łuczkowska K, Grabowicz A, Mozolewska-Piotrowska K, Safranow K, Kawa MP, Pałucha A, Krawczyk M, Sikora P, Matczyńska E, Machaliński B, Machalińska A. Associations of microRNAs, angiogenesis-regulating factors and CFH Y402H polymorphism – an attempt to search for systemic biomarkers in age-related macular degeneration Int J Mol Sci. 2019;20:5750
82. Vempati P, Popel AS, Mac Gabhann F. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning Cytokine Growth Factor Rev. 2014;25:1–19
83. Voutilainen-Kaunisto RM, Teräsvirta ME, Uusitupa MI, Niskanen LK. Age-related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects: a 10-year follow-up on evolution, risk factors, and prognostic significance Diabetes Care. 2000;23:1672–1678
84. Wang L, Lee AY, Wigg JP, Peshavariya H, Liu P, Zhang H. miRNA involvement in angiogenesis in age-related macular degeneration J Physiol Biochem. 2016a;72:583–592
85. Wang L, Lee AY, Wigg JP, Peshavariya H, Liu P, Zhang H. miR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse model Int J Mol Sci. 2016b;17:E895
86. Wang R, Zhao N, Li S, Fang JH, Chen MX, Yang J, Jia WH, Yuan Y, Zhuang SM. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42 Hepatology. 2013;58:642–653
87. Williams MA, Silvestri V, Craig D, Passmore AP, Silvestri G. The prevalence of age-related macular degeneration in Alzheimer’s disease J Alzheimers Dis. 2014;42:909–914
88. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease Prog Retin Eye Res. 2003;22:1–29
89. Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology. 2008;115:116–126
90. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis Lancet Glob Health. 2014;2:e106–116
91. Würdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, Weissleder R, Breakefield XO, Krichevsky AM. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells Cancer Cell. 2008;14:382–393
92. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L, Jiang BH. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis Nucleic Acids Res. 2012;40:761–774
93. Yoon SP, Grewal DS, Thompson AC, Polascik BW, Dunn C, Burke JR, Fekrat S. Renal microvascular and neurodegenerative changes in Alzheimer’s disease and mild cognitive impairment compared with control participants Ophthalmol Retina. 2019;3:489–499
94. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin JY, Ma X. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis Childs Nerv Syst. 2009;25:13–20
95. Zhou Q, Gallagher R, Ufret-Vincenty R, Li X, Olson EN, Wang S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23-27-24 clusters Proc Natl Acad Sci U S A. 2011;108:8287–8292
96. Zhou Q, Anderson C, Zhang H, Li X, Inglis F, Jayagopal A, Wang S. Repression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24 Mol Ther. 2014;22:378–389
C-Editors: Zhao M, Li JY; T-Editor: Jia Y
Conflicts of interest:The authors declare no conflicts of interest.
Copyright license agreement:The Copyright License Agreement has been signed by both authors before publication.
Data sharing statement:Datasets analyzed during the current study are available from the corresponding author on reasonable request.
Plagiarism check:Checked twice by iThenticate.
Peer review:Externally peer reviewed.